• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在英国一个大型类风湿性关节炎队列中，血清S100A9的预测价值及对依那西普的反应未得到证实。

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.

作者信息

Smith Samantha Louise, Plant Darren, Eyre Stephen, Hyrich Kimme, Morgan Ann W, Wilson Anthony G, Isaacs John D, Barton Anne

机构信息

Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, The University of Manchester.

National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre.

出版信息

Rheumatology (Oxford). 2017 Jun 1;56(6):1019-1024. doi: 10.1093/rheumatology/kew387.

DOI:10.1093/rheumatology/kew387
PMID:28096457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5445600/
Abstract

OBJECTIVE

The aim was to correlate protein concentrations of S100A9 in pretreatment serum samples with response to the tumour-necrosis factor (TNF) inhibitor drugs etanercept in a large UK replication cohort.

METHODS

Pretreatment serum samples from patients with RA (n = 236) about to commence treatment with etanercept had S100A9 serum concentration measured using an ELISA. Following the experimental procedure, S100A9 concentrations were analysed with respect to EULAR response.

RESULTS

No evidence of association between S100A9 concentration and EULAR response to the TNF-inhibitor biologic drug etanercept was observed following multinomial logistic regression analysis (non-responder vs moderate responder, P = 0.957; and non-responder vs good responder, P = 0.316). Furthermore, no significant associations were observed when correlating pretreatment S100A9 concentrations with clinical parameters of disease activity (P > 0.05).

CONCLUSION

In the largest replication cohort conducted to date, no evidence for association was observed to support the use of S100A9 as a clinical biomarker predictive of response to the TNF-inhibitor biologic drug etanercept.

摘要

目的

旨在将英国一个大型重复队列中，肿瘤坏死因子（TNF）抑制剂药物依那西普治疗前血清样本中S100A9的蛋白质浓度与治疗反应相关联。

方法

对即将开始接受依那西普治疗的类风湿关节炎患者（n = 236）的治疗前血清样本，使用酶联免疫吸附测定法（ELISA）测量S100A9血清浓度。按照实验步骤，分析S100A9浓度与欧洲抗风湿病联盟（EULAR）反应的关系。

结果

多项逻辑回归分析后，未观察到S100A9浓度与EULAR对TNF抑制剂生物药物依那西普的反应之间存在关联证据（无反应者与中度反应者相比，P = 0.957；无反应者与良好反应者相比，P = 0.316）。此外，将治疗前S100A9浓度与疾病活动的临床参数相关联时，未观察到显著关联（P > 0.05）。

结论

在迄今为止进行的最大规模重复队列研究中，未观察到支持将S100A9用作预测TNF抑制剂生物药物依那西普反应的临床生物标志物的关联证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c0/5445600/7054b525e253/kew387f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c0/5445600/7054b525e253/kew387f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c0/5445600/7054b525e253/kew387f1.jpg

相似文献

1
The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.在英国一个大型类风湿性关节炎队列中，血清S100A9的预测价值及对依那西普的反应未得到证实。
Rheumatology (Oxford). 2017 Jun 1;56(6):1019-1024. doi: 10.1093/rheumatology/kew387.
2
Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.使用蛋白质组学方法鉴定S100A9作为类风湿关节炎中对甲氨蝶呤/依那西普联合治疗反应性的生物标志物。
PLoS One. 2014 Dec 29;9(12):e115800. doi: 10.1371/journal.pone.0115800. eCollection 2014.
3
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.类风湿关节炎伴抗药物抗体患者对生物制剂的反应。
JAMA Netw Open. 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098.
4
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.英国、法国和德国生物性改善病情抗风湿药在停用依那西普后治疗类风湿关节炎的真实世界疗效
Clin Ther. 2017 Aug;39(8):1618-1627. doi: 10.1016/j.clinthera.2017.06.009. Epub 2017 Jul 17.
5
Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.在全血类风湿性关节炎样本中研究CD11c表达作为对肿瘤坏死因子抑制剂生物制剂反应的潜在基因组生物标志物。
Arthritis Res Ther. 2015 Dec 14;17:359. doi: 10.1186/s13075-015-0868-y.
6
Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.触珠蛋白-α1、-α2、维生素D结合蛋白和载脂蛋白C-III作为类风湿关节炎中依那西普药物反应的预测指标。
Arthritis Res Ther. 2015 Mar 6;17(1):45. doi: 10.1186/s13075-015-0553-1.
7
Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.血清白细胞介素-6和生存素水平可预测确诊类风湿关节炎患者对依那西普治疗的临床反应。
Mod Rheumatol. 2018 Jan;28(1):126-132. doi: 10.1080/14397595.2017.1317384. Epub 2017 Jun 28.
8
Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis.差异甲基化作为依那西普治疗类风湿关节炎患者反应的生物标志物。
Arthritis Rheumatol. 2016 Jun;68(6):1353-60. doi: 10.1002/art.39590. Epub 2016 Apr 21.
9
Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.血清中的肿瘤坏死因子-α/依那西普复合物可预测依那西普治疗血清阴性类风湿关节炎的长期疗效。
Scand J Rheumatol. 2018 Jan;47(1):22-26. doi: 10.1080/03009742.2017.1290822. Epub 2017 May 9.
10
Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.抗药物抗体水平与类风湿关节炎阿达木单抗和依那西普治疗的血清药物谷浓度和治疗反应的显著相关性。
Ann Rheum Dis. 2015 Mar;74(3):e16. doi: 10.1136/annrheumdis-2013-203893. Epub 2014 Jan 17.

引用本文的文献

1
Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?使用蛋白质组学策略对类风湿关节炎进行个性化治疗决策：如何开始以及何时停止？
Clin Proteomics. 2023 Jun 10;20(1):22. doi: 10.1186/s12014-023-09411-2.
2
Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.在 ESPOIR 队列中验证维生素 K 依赖性蛋白 S（PROS）作为一种潜在的生物标志物，能够预测对甲氨蝶呤/依那西普联合治疗的反应。
Arthritis Res Ther. 2022 Mar 21;24(1):72. doi: 10.1186/s13075-022-02762-5.
3
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.

本文引用的文献

1
Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.使用蛋白质组学方法鉴定S100A9作为类风湿关节炎中对甲氨蝶呤/依那西普联合治疗反应性的生物标志物。
PLoS One. 2014 Dec 29;9(12):e115800. doi: 10.1371/journal.pone.0115800. eCollection 2014.
2
High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort.早期类风湿关节炎中高水平的转移诱导蛋白S100A4与治疗结果：来自PERAC队列的数据。
Biomarkers. 2015 Feb;20(1):47-51. doi: 10.3109/1354750X.2014.989544. Epub 2014 Dec 9.
3
血清钙卫蛋白：类风湿关节炎和中轴型脊柱关节炎有前景的生物标志物。
Arthritis Res Ther. 2020 May 6;22(1):105. doi: 10.1186/s13075-020-02190-3.
4
Rheumatoid arthritis: S100A9 does not predict response to etanercept.类风湿关节炎：S100A9不能预测对依那西普的反应。
Nat Rev Rheumatol. 2017 Mar;13(3):130. doi: 10.1038/nrrheum.2017.13. Epub 2017 Feb 2.
MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
MRP8/14 血清水平是类风湿关节炎患者对生物治疗反应的强有力预测指标。
Ann Rheum Dis. 2015 Mar;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923. Epub 2013 Dec 2.
4
Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.类风湿关节炎中的钙卫蛋白：在横断面和纵向队列研究中的疾病活动相关性。
Mol Diagn Ther. 2013 Feb;17(1):49-56. doi: 10.1007/s40291-013-0016-9.
5
The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab.可溶性生物标志物钙卫蛋白（一种 S100 蛋白）与超声滑膜炎评分相关，并且对阿达木单抗治疗的类风湿关节炎患者的变化敏感。
Arthritis Res Ther. 2011;13(5):R178. doi: 10.1186/ar3503. Epub 2011 Oct 26.
6
Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.血清 S100A8/9（钙卫蛋白）水平的降低与近期发病的类风湿关节炎患者总肿胀关节数的改善相关。
Arthritis Res Ther. 2011 Jul 26;13(4):R122. doi: 10.1186/ar3426.
7
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study.早期治疗类风湿关节炎对放射学进展的长期影响：基于人群的队列研究。
Rheumatology (Oxford). 2011 Jun;50(6):1106-10. doi: 10.1093/rheumatology/keq424. Epub 2011 Jan 21.
8
Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis.早期使用并及时接受首种疾病修正抗风湿药物可预测炎症性多关节炎患者的长期功能。
Ann Rheum Dis. 2010 Apr;69(4):689-95. doi: 10.1136/ard.2009.108639. Epub 2009 Oct 26.
9
Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis.转移性诱导 S100A4 蛋白与类风湿关节炎的疾病活动有关。
Rheumatology (Oxford). 2009 Dec;48(12):1590-4. doi: 10.1093/rheumatology/kep316. Epub 2009 Oct 14.
10
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.在对第一种抗TNF药物无反应的患者中，转换抗TNF治疗对健康评估问卷（HAQ）反应的影响。
Rheumatology (Oxford). 2008 Jul;47(7):1000-5. doi: 10.1093/rheumatology/ken127. Epub 2008 Apr 17.